🎉 M&A multiples are live!
Check it out!

Allogene Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Allogene Therapeutics and similar public comparables like Pharming, Julphar, and Vivoryon Therapeutics.

Allogene Therapeutics Overview

About Allogene Therapeutics

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.


Founded

2017

HQ

United States of America
Employees

229

Website

allogene.com

Financials

LTM Revenue $19K

LTM EBITDA -$257M

EV

$109M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Allogene Therapeutics Financials

Allogene Therapeutics has a last 12-month revenue of $19K and a last 12-month EBITDA of -$257M.

In the most recent fiscal year, Allogene Therapeutics achieved revenue of $22K and an EBITDA of -$243M.

Allogene Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Allogene Therapeutics valuation multiples based on analyst estimates

Allogene Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.1M $22K XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$300M -$243M XXX XXX XXX
EBITDA Margin -316098% -1106032% XXX XXX XXX
Net Profit -$333M -$327M XXX XXX XXX
Net Margin -350139% -1487568% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Allogene Therapeutics Stock Performance

As of April 15, 2025, Allogene Therapeutics's stock price is $1.

Allogene Therapeutics has current market cap of $311M, and EV of $109M.

See Allogene Therapeutics trading valuation data

Allogene Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$109M $311M XXX XXX XXX XXX $-1.29

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Allogene Therapeutics Valuation Multiples

As of April 15, 2025, Allogene Therapeutics has market cap of $311M and EV of $109M.

Allogene Therapeutics's trades at 5625.7x LTM EV/Revenue multiple, and -0.4x LTM EBITDA.

Analysts estimate Allogene Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Allogene Therapeutics and 10K+ public comps

Allogene Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $109M XXX XXX XXX
EV/Revenue 4953.1x XXX XXX XXX
EV/EBITDA -0.4x XXX XXX XXX
P/E -1.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Allogene Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Allogene Therapeutics Valuation Multiples

Allogene Therapeutics's NTM/LTM revenue growth is -28%

Allogene Therapeutics's revenue per employee for the last fiscal year averaged $0K, while opex per employee averaged $1.1M for the same period.

Over next 12 months, Allogene Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Allogene Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Allogene Therapeutics and other 10K+ public comps

Allogene Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -77% XXX XXX XXX XXX
EBITDA Margin -1106032% XXX XXX XXX XXX
EBITDA Growth -19% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -1106060% XXX XXX XXX XXX
Revenue per Employee $0K XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 296386% XXX XXX XXX XXX
R&D Expenses to Revenue 874086% XXX XXX XXX XXX
Opex to Revenue 1170473% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Allogene Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Allogene Therapeutics M&A and Investment Activity

Allogene Therapeutics acquired  XXX companies to date.

Last acquisition by Allogene Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Allogene Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Allogene Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Allogene Therapeutics

When was Allogene Therapeutics founded? Allogene Therapeutics was founded in 2017.
Where is Allogene Therapeutics headquartered? Allogene Therapeutics is headquartered in United States of America.
How many employees does Allogene Therapeutics have? As of today, Allogene Therapeutics has 229 employees.
Who is the CEO of Allogene Therapeutics? Allogene Therapeutics's CEO is Dr. David D. Chang, M.D.,PhD.
Is Allogene Therapeutics publicy listed? Yes, Allogene Therapeutics is a public company listed on NAS.
What is the stock symbol of Allogene Therapeutics? Allogene Therapeutics trades under ALLO ticker.
When did Allogene Therapeutics go public? Allogene Therapeutics went public in 2018.
Who are competitors of Allogene Therapeutics? Similar companies to Allogene Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Allogene Therapeutics? Allogene Therapeutics's current market cap is $311M
What is the current revenue of Allogene Therapeutics? Allogene Therapeutics's last 12-month revenue is $19K.
What is the current EBITDA of Allogene Therapeutics? Allogene Therapeutics's last 12-month EBITDA is -$257M.
What is the current EV/Revenue multiple of Allogene Therapeutics? Current revenue multiple of Allogene Therapeutics is 5625.7x.
What is the current EV/EBITDA multiple of Allogene Therapeutics? Current EBITDA multiple of Allogene Therapeutics is -0.4x.
What is the current revenue growth of Allogene Therapeutics? Allogene Therapeutics revenue growth between 2023 and 2024 was -77%.
Is Allogene Therapeutics profitable? Yes, Allogene Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.